Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with a type 1 myocardial infarction within the previous 6 months.~2. Subjects must be ≥65 years old, presenting with at least one of the following additional conditions:~   * Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin.~  * Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2.~  * Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical report.~  * Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).~  * Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, not resulting in death.~  * Age ≥ 75 years.~3. Signing informed consent.~Exclusion Criteria:~1. Unable to sign informed consent.~2. Contraindications to any of the components of the polypill.~3. Living in a nursing home.~4. Mental illness limiting the capacity of self-care.~5. Participating in another clinical trial.~6. Severe congestive heart failure (NYHA III-IV).~7. Severe renal disease (Creatinine Clearance (CrCl) \<30ml/min/1.73 m2).~8. Need for oral anticoagulation at the time of randomization or planned in the future months.~9. Any condition limiting life expectancy \<2 years, including but not limited to active malignancy.~10. Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation).~11. Scheduled coronary revascularization (patients can be randomized after final revascularization is completed within the prespecified timeframe).~12. Do not agree to the filing, forwarding and use of his/ her pseudonymised data.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Prevention for Secondary CV (Type: ACTIVE_COMPARATOR): Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
- Cardiovascular Polypill (Type: EXPERIMENTAL): Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).